argenex’s (ARGX) Buy Rating Reaffirmed at DZ Bank

argenex (NASDAQ:ARGX)‘s stock had its “buy” rating reissued by equities research analysts at DZ Bank in a report issued on Friday.

A number of other equities analysts also recently commented on the stock. Oppenheimer lifted their price objective on shares of argenex from $1,014.00 to $1,037.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Weiss Ratings lowered shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 23rd. Citigroup increased their target price on shares of argenex from $1,152.00 to $1,182.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Wells Fargo & Company raised their price target on shares of argenex from $1,350.00 to $1,415.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. Finally, Wall Street Zen lowered shares of argenex from a “buy” rating to a “hold” rating in a report on Saturday, September 19th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and a consensus price target of $1,154.94.

argenex Stock Down 0.8%

Shares of ARGX traded down $6.96 during mid-day trading on Friday, hitting $818.07. The stock had a trading volume of 104,254 shares, compared to its average volume of 345,039. argenex has a fifty-two week low of $661.85 and a fifty-two week high of $1,072.75. The company has a market cap of $51.18 billion, a PE ratio of 31.37, a PEG ratio of 0.86 and a beta of 0.44. The company’s fifty day simple moving average is $959.93 and its two-hundred day simple moving average is $877.49.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.86 by $1.46. The business had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. Equities analysts expect that argenex will post 28.83 earnings per share for the current year.

Institutional Investors Weigh In On argenex

Several large investors have recently added to or reduced their stakes in ARGX. Whipplewood Advisors LLC bought a new stake in argenex in the first quarter valued at $28,000. Eastern Bank acquired a new position in shares of argenex during the second quarter valued at $32,000. Axiom Investment Management LLC bought a new position in shares of argenex during the first quarter worth about $50,000. WPG Advisers LLC grew its position in shares of argenex by 17.8% during the first quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after acquiring an additional 13 shares during the last quarter. Finally, Fifth Third Bancorp grew its position in shares of argenex by 616.7% during the first quarter. Fifth Third Bancorp now owns 172 shares of the company’s stock worth $126,000 after acquiring an additional 148 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

About argenex

argenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.

argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn).